ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) CEO Philippe Deschamps tells Proactive's Stephen Gunnion that the company has launched its second orthopedic development program in meniscus repair following the development completion of its preclinical arthroscopic surgery program.
Deschamps says the company is already in clinical development in its rotator cuff tear repair surgery.
The new program, which is funded by a previously announced Axelys grant of $750,000, demonstrates and confirms the multiple indications potential of ChitogenX's technology platform, he adds.
#proactiveinvestors #ChitogenX #meniscus #rotatorcuff #CSE #OTCQB